Stock’s Earnings in Focus: Earth Science Tech Inc (ETST), Easton Pharmaceuticals Inc (EAPH), HempAmericana Inc (HMPQ)

Stock’s Earnings in Focus: Earth Science Tech Inc (ETST), Easton Pharmaceuticals Inc (EAPH), HempAmericana Inc (HMPQ)

Stock’s Earnings in Focus: Earth Science Tech Inc (ETST), Easton Pharmaceuticals Inc (EAPH), HempAmericana Inc (HMPQ)

Earth Science Tech Inc (OTCMKTS:ETST) reported the plunge of -6.25% and closed at $1.50, with the total traded volume of 12,266.00 shares. During last trade its minimum price was $1.38 and it gained its highest price of $1.61 and has a total of 40.91 million outstanding shares.

On March 14, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices is proud to announce its subsidiaries Cannabis Therapeutic, Inc. and Earth Science Pharmaceutical, Inc. the nomination of Kim Foster-Cunningham to the post of Project Manager for the MSN-2 medical device project; and Denis Babin of SDB Import/Export, Inc. as international marketing consultant for Cannabis Therapeutics and Earth Science Pharmaceutical products.

Ms. Foster-Cunningham’s immediate focus is preparatory phase of the pre-market clinical trial of the MSN-2 medical device. The MSN-2 device is a revolutionary medical instrument for the detection and diagnosis of Chlamydia and Gonorrhea, from previous announcement, (ETST Announces 60-Patient Clinical Prelaunch Study for its MSN-2 Medical Device for the Diagnosis of Chlamydia & Gonorrhea, ETST Elects Dr. Michel Aubé as New CEO & CSO, and Nickolas Tabraue as President.)

Ms. Foster-Cunningham, whom holds a degree in sales and marketing, is recognized for her expertise in business networking and her solid business expertise. She is a sought-after speaker throughout the USA and Canada, delivering conferences on her proactive approach to general health and self-care. Passionate about individual sports, she is a half marathon runner and a triathlete. Always enthusiastic about transmitting her passion for health and business development, this project is “her new baby”.

“I love my work, especially when it allows me to bring my passion for health and business development together, and to bring them to other people,’ says Foster-Cunningham. “This project is my new baby, and I’m excited about the prospects of helping it grow to maturity.”

Easton Pharmaceuticals Inc (OTCMKTS:EAPH) showing dropped of -5.56% and closed at $0.0255, after gaining total volume of 3.51M shares. Its earnings per share (EPS) is $0.00 and its beta value stands at -16.79 points and has total market capitalization of $22.94 million and a total of 932.73 million outstanding shares.

Easton Pharmaceuticals Inc (EAPH) on March 22, 2017 announced it has forwarded together with BMV Medica a $300,000 payment to CommonSense of Israel clearing the way for the closing of an anticipated exclusive sub-distribution agreement with a major, multi-national, pharmaceutical company for the women’s diagnostic product AL-Sense (AmnioSense). In addition, Easton / BMV through their commercial alliance partner Ackerman Pharma, provides update on the regulatory filing of Generic Cancer Drug Paclitaxell, currently licensed together with Docetaxel through Biolyse Pharma of St. Catherines Ontario, through “fast-track” third-party authorized reviewer DefiLatina Healthcare, S.A. de C.V. towards regulatory approval in Mexico and other parts of Latin America.

Easton Pharmaceuticals / BMV Medica, last week advanced a $300,000 payment to CommonSense of Israel as an additional payment to secure the rights to women’s diagnostic products AL-Sense and VS-Sense, with the majority of the payment advanced by Easton Pharmaceuticals. The payment was advanced after a detailed marketing plan was submitted to CommonSense by Easton / BMV and its soon to be sub-distribution partner, which competed with another large company who was attempting to also acquire the rights to AL-Sense. The payment by Easton / BMV was the last hurdle, prior to a sub-distribution agreement being executed with a multi-national pharmaceutical company for AL-Sense who have sales in the billions of dollars. Easton is now exchanging and reviewing documents and final agreements towards the execution of the sub-distribution agreement which would result in the launch of its second product (AmnioSense), starting in Mexico and Central America.

HempAmericana Inc (OTCMKTS:HMPQ) increased 4.94% closed at $0.00850 and traded with total volume of 401,479.00 shares, while the average trading remained 3.23M shares. During last trade its minimum price was $0.01 and it gained the highest price of $0.01. Its market capitalization was $1.35 million.

HempAmericana, Inc. researches, develops, and sells products made of industrial hemp in the United States. It provides hemp-based concrete, hemp bags, hemp seeds for consumption, hemp clothing, and hemp rolling paper products. HempAmericana, Inc. was founded in 2014 and is based in New York, New York.



Leave a reply


There are no comments on this post.

Risk Warning: Investing in digital currencies, stocks, shares and other securities, commodities, currencies and other derivative investment products (e.g. contracts for difference (“CFDs”) is speculative and carries a high level of risk. Each investment is unique and involves unique risks.

CFDs and other derivatives are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how an investment works and whether you can afford to take the high risk of losing your money.

Cryptocurrencies can fluctuate widely in prices and are, therefore, not appropriate for all investors. Trading cryptocurrencies is not supervised by any EU regulatory framework. Past performance does not guarantee future results. Any trading history presented is less than 5 years old unless otherwise stated and may not suffice as a basis for investment decisions. Your capital is at risk.

When trading in stocks your capital is at risk.

Past performance is not an indication of future results. Trading history presented is less than 5 years old unless otherwise stated and may not suffice as a basis for investment decisions. Prices may go down as well as up, prices can fluctuate widely, you may be exposed to currency exchange rate fluctuations and you may lose all of or more than the amount you invest. Investing is not suitable for everyone; ensure that you have fully understood the risks and legalities involved. If you are unsure, seek independent financial, legal, tax and/or accounting advice. This website does not provide investment, financial, legal, tax or accounting advice. Some links are affiliate links. For more information please read our full risk warning and disclaimer.